11 beta-hydroxysteroid dehydrogenase type 1 and obesity

Other symptoms reported by sufferers include but are not limited to: nausea, vomiting, fatigue, photophobia (dislike of and pain caused by bright light), problems with balance and spatial awareness, aphasia (difficulty using or understanding words), disorientation, loss of short-term memory (sometimes also long-term memory loss), confusion, feeling 'spaced out', decreased depth perception and peripheral vision. Some children are often too young to report their symptoms adequately and can present with many nonspecific symptoms such as mood swings and more. Although many sufferers have symptoms in common, each sufferer is an individual and should be treated accordingly.

Dehydroepiandrosterone comes into subsequent oxidative transformation with production of 16Alpha-hydroxydehydroepiandrosterone . This oxidation is catalyzed by Cytochrome P450, family 3, subfamily A, polypeptide 7 ( CYP3A7) [10] , [11] , [12] and Cytochrome P450, family 3, subfamily A, polypeptide 4 ( CYP3A4) [13] , [10] , [11] . Oxidative metabolite of this reaction as well as Dehydroepiandrosterone can be further sulfated by steroid sulfatase (microsomal), isozyme S ( STS ) [14] , [15] , [16] , [15] , [14] . Dehydroepiandrosterone and Dehydroepiandrosterone sulfate can be transformed into other compounds with hormonal activity, Androstendiol and Androstendiol sulfate , respectively. These two reactions are catalyzed by Hydroxysteroid (17-beta) dehydrogenase 1 ( HSD17B1) [17] , [18] , [17] , [18] , Hydroxysteroid (17-beta) dehydrogenase 2 ( HSD17B2) [19] , [20] , [20] , [21] , and Hydroxysteroid (17-beta) dehydrogenase 7 ( HSD17B7 ) [22] , [23] , [23] , [24] .

There is an interesting article that appeared couple of months after this post in 2009 at . Swiss researchers administered about 500 mg of licorice (obtained from China as a powder) to 20 hemodialysis patients twice a day through cookies, and got interesting results: A reduced frequency of severe hyperkalemia (which they defined as > 6 mmol/L) when compared to placebo was observed; and within days, it produced a sustained decline of potassium prior to dialysis, prompting higher dialysate K concentrations, they measured the ratio of plasma cortisol/cortisone and as expected it was noted to be elevated as well as a reduction of also/renin ratio. The treatment seemed to be well tolerated, no differences in BP (most likely due to the dialysis on BP) or interdialytic weight gain.
Here is the reference, is free: http://kidney-/article/S0085-2538(15)54066-0/pdf

11 beta-hydroxysteroid dehydrogenase type 1 and obesity

11 beta-hydroxysteroid dehydrogenase type 1 and obesity

Media:

11 beta-hydroxysteroid dehydrogenase type 1 and obesity11 beta-hydroxysteroid dehydrogenase type 1 and obesity11 beta-hydroxysteroid dehydrogenase type 1 and obesity11 beta-hydroxysteroid dehydrogenase type 1 and obesity11 beta-hydroxysteroid dehydrogenase type 1 and obesity

http://buy-steroids.org